Traumatic Brain Injury (TBI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Traumatic Brain Injury (TBI) Market Outlook
Thelansis’s “Traumatic Brain Injury
(TBI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2024 To 2034" covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Traumatic Brain Injury (TBI)
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Traumatic Brain Injury (TBI) Overview
Traumatic
Brain Injury (TBI) is a disruption in the brain’s normal functioning caused by
physical impact to the head, such as a blow, bump, or jolt, or when an object
penetrates the skull and enters the brain tissue. Clinical signs indicating an
alteration in normal brain function include loss of consciousness or decreased
consciousness, memory loss (amnesia) for events before or after the injury,
focal neurological deficits like muscle weakness or loss of vision, and changes
in mental state such as disorientation or difficulty concentrating. The frontal
and temporal areas of the brain are primarily affected. Mild TBI, also known as
brain concussion, has gained significant attention due to its potential adverse
neuropsychological outcomes in civilian populations (e.g., athletes in contact
sports) and military personnel. Moderate to severe TBI is a major cause of
injury-related death and disability. TBI symptoms can range from mild to
severe, depending on the extent of brain damage. Mild cases may temporarily alter
mental state or consciousness, while severe cases can lead to prolonged
unconsciousness, coma, or even death. There are two main types of head
injuries: Penetrating TBI, which occurs when an object pierces the skull and
damages a specific area of the brain, and non-penetrating TBI, caused by a
strong external force that moves the brain within the skull. Causes of
non-penetrating TBI include falls, motor vehicle accidents, sports injuries,
blast injuries, and being struck by an object. Clinical features of TBI may
include prolonged coma, headache, nausea, aphasia (language difficulties),
seizures, amnesia, and behavioral abnormalities such as aggression and anxiety.
These symptoms can occur within seconds to minutes after the injury and may
persist for months or years. The severity of TBI is evaluated using measures
such as level of consciousness (LOC), altered mental status (AMS),
post-traumatic amnesia (PTA), and the Glasgow Coma Scale (GCS). TBI causes
damage to neuronal tissues, which can be classified into two categories:
primary injury, directly caused by the mechanical forces during the initial
insult, and secondary injury, which refers to further tissue and cellular
damage after the primary insult. The differential diagnosis for TBI includes
stroke, spontaneous acute subdural hematoma, Alzheimer’s disease, cerebral
aneurysms, frontal lobe syndrome, and hydrocephalus.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment